CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders

Publisher： Bentham Science Publishers

E-ISSN： 1875-5607|7|3|253-273

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.7, Iss.3, 2007-03, pp. : 253-273

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for Therapy

By  

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 4, Iss. 1, 2004-03 ,pp. : 11-18

Bentham Science Publishers

Access to resources Recommend Favorite

Dipeptidyl-Peptidase IV (DPP IV/CD26)-Activated Prodrugs: A Successful Strategy for Improving Water Solubility and Oral Bioavailability

By  

Current Medicinal Chemistry, Vol. 22, Iss. 8, 2015-03 ,pp. : 1041-1054

Bentham Science Publishers

Access to resources Recommend Favorite

Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme

By  

Current Medicinal Chemistry, Vol. 16, Iss. 23, 2009-08 ,pp. : 2943-2951

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

By Drucker DJ  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 87-100

Informa Healthcare

Access to resources Recommend Favorite

The Therapeutic Potential of Inhibitors of Dipeptidyl Peptidase IV (DPP IV) and Related Proline-Specific Dipeptidyl Aminopeptidases

By  

Current Medicinal Chemistry, Vol. 12, Iss. 8, 2005-04 ,pp. : 971-998

Bentham Science Publishers

Access to resources Recommend Favorite